Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370926 | 0.93 | BACE1 (0.42) | BACE1BACE2DPP4DPP8DPP9 | |
| SCHEMBL29790226 | 0.92 | ERAP2 (0.39) | BACE1BACE2CTSDERBB2ERAP2 | |
| SCHEMBL30874953 | 0.91 | DPP4 (0.39) | BACE1BACE2DPP4DPP8DPP9 | |
| SCHEMBL30974452 | 0.87 | BACE1 (0.39) | BACE1BACE2CTSD | |
| SCHEMBL29961965 | 0.86 | CALCRL (0.37) | BACE1BACE2ERBB2 | |
| SCHEMBL21766737 | 0.85 | MAGI3 (0.39) | BACE1BACE2ERAP2ERAP1LNPEP | |
| SCHEMBL21766784 | 0.84 | ERAP2 (0.37) | BACE1BACE2ERBB2ERAP2ERAP1 | |
| SCHEMBL31302648 | 0.84 | BACE1 (0.47) | BACE1BACE2CTSD | |
| SCHEMBL29904276 | 0.84 | BACE1 (0.41) | BACE1BACE2CTSD | |
| SCHEMBL30919404 | 0.84 | BACE1 (0.41) | BACE1BACE2CTSDERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12269856-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-12234300-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4188413-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| EP-4091624-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-4025592-A1 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114729022-A | Conjugated hepcidin mimetics | 领导医疗有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022026629-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | BACE1 1262/4885BACE2 1803/4885DPP4 662/4885 |
| US-12269856-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | BACE1 1506/4885BACE2 2817/4885DPP4 1934/4885 |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1349/4885BACE2 2326/4885DPP4 898/4885 |
| US-12234300-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885DPP4 841/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1278/4885BACE2 2242/4885DPP4 984/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885DPP4 841/4885 |
| US-20250340608-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | BACE1 1506/4885BACE2 2817/4885DPP4 1934/4885 |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | BACE1 3603/4885BACE2 4183/4885DPP4 2057/4885 |
| US-20220348626-A1 | HEPCIDIN ANALOGUES AND USES THEREOF | HAMP, SLC40A1, FTH1 | BACE1 1506/4885BACE2 2817/4885DPP4 1934/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1252/4885BACE2 2190/4885DPP4 841/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | BACE1 1364/4885BACE2 2152/4885DPP4 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.